CBP-201 clinical trials
Also written CBP-201.
How each study uses CBP-201 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Connect Biopharm LLC (9)
Studies
Open first, then newest update. How each study uses CBP-201 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)CompletedPhase 2Connect Biopharm LLCNCT06940154Written as Rademikibart in prefilled syringe
- Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)CompletedPhase 2Connect Biopharm LLCNCT06940141Written as Rademikibart in prefilled syringe
- A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in ChinaCompletedPhase 2Connect Biopharm LLCNCT05017480Written as CBP-201
- Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 InflammationCompletedPhase 2Connect Biopharm LLCNCT04773678Written as CBP-201
- A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe ADActive, not recruitingPhase 2Connect Biopharm LLCNCT05905133Written as CBP-201
- A Study to Evaluate the Pharmacokinetics Similarity of CBP-201 in Healthy Adult Chinese SubjectsCompletedPhase 1Connect Biopharm LLCNCT05917782Written as Test drug (T1): CBP-201 injection (pre-filled syringe, 150 mg/1 mL)
- A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal PolypsTerminatedPhase 2Connect Biopharm LLCNCT04783389Written as CBP-201
- A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic DermatitisCompletedPhase 2Connect Biopharm LLCNCT04444752Written as CBP-201
- CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic DermatitisWithdrawnPhase 3Connect Biopharm LLCNCT05614817Written as CBP-201